These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 10647505

  • 1. Potentiation of BCNU antitumor efficacy by 9-substituted O6-benzylguanines. Effect of metabolism.
    Kokkinakis DM, Moschel RC, Pegg AE, Schold SC.
    Cancer Chemother Pharmacol; 2000; 45(1):69-77. PubMed ID: 10647505
    [Abstract] [Full Text] [Related]

  • 2. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity.
    Marathi UK, Dolan ME, Erickson LC.
    Cancer Res; 1994 Aug 15; 54(16):4371-5. PubMed ID: 8044784
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
    Kokkinakis DM, Bocangel DB, Schold SC, Moschel RC, Pegg AE.
    Clin Cancer Res; 2001 Feb 15; 7(2):421-8. PubMed ID: 11234899
    [Abstract] [Full Text] [Related]

  • 7. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
    Phillips WP, Willson JK, Markowitz SD, Zborowska E, Zaidi NH, Liu L, Gordon NH, Gerson SL.
    Cancer Res; 1997 Nov 01; 57(21):4817-23. PubMed ID: 9354444
    [Abstract] [Full Text] [Related]

  • 8. Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo.
    Marathi UK, Dolan ME, Erickson LC.
    Biochem Pharmacol; 1994 Nov 29; 48(11):2127-34. PubMed ID: 7802703
    [Abstract] [Full Text] [Related]

  • 9. Prolonged depletion of O6-methylguanine DNA methyltransferase activity following exposure to O6-benzylguanine with or without streptozotocin enhances 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity in vitro.
    Marathi UK, Kroes RA, Dolan ME, Erickson LC.
    Cancer Res; 1993 Sep 15; 53(18):4281-6. PubMed ID: 8364924
    [Abstract] [Full Text] [Related]

  • 10. O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials.
    Keir ST, Dolan ME, Pegg AE, Lawless A, Moschel RC, Bigner DD, Friedman HS.
    Cancer Chemother Pharmacol; 2000 Sep 15; 45(6):437-40. PubMed ID: 10854129
    [Abstract] [Full Text] [Related]

  • 11. Depletion of O6-methylguanine-DNA methyltransferase and potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea antitumor activity by O6-benzylguanine in vitro.
    Chen JM, Zhang YP, Moschel RC, Ikenaga M.
    Carcinogenesis; 1993 May 15; 14(5):1057-60. PubMed ID: 8504466
    [Abstract] [Full Text] [Related]

  • 12. Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
    Kreklau EL, Pollok KE, Bailey BJ, Liu N, Hartwell JR, Williams DA, Erickson LC.
    Mol Cancer Ther; 2003 Dec 15; 2(12):1321-9. PubMed ID: 14707273
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Davis BM, Reese JS, Koç ON, Lee K, Schupp JE, Gerson SL.
    Cancer Res; 1997 Nov 15; 57(22):5093-9. PubMed ID: 9371508
    [Abstract] [Full Text] [Related]

  • 16. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
    Bobola MS, Silber JR, Ellenbogen RG, Geyer JR, Blank A, Goff RD.
    Clin Cancer Res; 2005 Apr 01; 11(7):2747-55. PubMed ID: 15814657
    [Abstract] [Full Text] [Related]

  • 17. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
    Friedman HS, Dolan ME, Moschel RC, Pegg AE, Felker GM, Rich J, Bigner DD, Schold SC.
    J Natl Cancer Inst; 1992 Dec 16; 84(24):1926-31. PubMed ID: 1334154
    [Abstract] [Full Text] [Related]

  • 18. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
    Koç ON, Reese JS, Davis BM, Liu L, Majczenko KJ, Gerson SL.
    Hum Gene Ther; 1999 Apr 10; 10(6):1021-30. PubMed ID: 10223735
    [Abstract] [Full Text] [Related]

  • 19. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
    Loktionova NA, Xu-Welliver M, Crone TM, Kanugula S, Pegg AE.
    Biochem Pharmacol; 1999 Jul 15; 58(2):237-44. PubMed ID: 10423163
    [Abstract] [Full Text] [Related]

  • 20. Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Felker GM, Friedman HS, Dolan ME, Moschel RC, Schold C.
    Cancer Chemother Pharmacol; 1993 Jul 15; 32(6):471-6. PubMed ID: 8258196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.